PLAU and neoplasm: Next, we determined if having high (top 50% of tumours) versus low (bottom 50% of tumours) percentages of positive ALDH1A3, tPA, uPA, and PAI‐2 cells, or having combined high ALDH1A3 and tPA (ALDH1A3+/tPA+) versus low ALDH1A3−/tPA−, high ALDH1A3 and uPA (ALDH1A3+/uPA+) versus low ALDH1A3−/uPA−, high ALDH1A3 and low PAI‐2 (ALDH1A3+/PAI‐2−) versus low ALDH1A3 and high PAI‐2 (ALDH1A3−/PAI‐2+) cells in patient tumours is associated with later disease progression.